|Author: Jo Frowde. Scleroderma is highly variable. See Types of Scleroderma. Read Disclaimer|
Uptravi is marketed by San Francisco-based Actelion Pharmaceuticals US, Inc.
Uptravi® (selexipag) is an oral IP prostacyclin receptor agonist marketed by Actelion Pharmaceuticals US, Inc., which was approved by the US FDA for the treatment of pulmonary arterial hypertension in December 2015. Common side effects include headache, diarrhea, jaw pain, nausea, muscle pain (myalgia), vomiting, pain in an extremity, and flushing. ISN.
Uptravi (selexipag). About this treatment for pulmonary hypertension, including the GRIPHON clinical trial results, safety and tolerability, and dosing information. Actelion.
Selexipag for the treatment of connective tissue disease–associated pulmonary arterial hypertension (PAH). Selexipag delayed progression of PAH and was well–tolerated among PAH–Connective Tissue Disease patients, including those with PAH–Scleroderma and PAH–Systemic Lupus Erythematosus. PubMed, Eur Respir J, 2017 Aug 17;50(2).
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.
We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: